Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease

Hum Gene Ther. 1998 May 20;9(8):1237-50. doi: 10.1089/hum.1998.9.8-1237.

Authors

M A Roskrow¹, C M Rooney, H E Heslop, M K Brenner, R A Krance, M V Gresik, K McClain, L K Aguilar, B Grilley, E Rob, G Carrum

Affiliation

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.

PMID: 9625264
DOI: 10.1089/hum.1998.9.8-1237

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I

MeSH terms

Anti-Bacterial Agents / pharmacology*
Cell Line
Drug Resistance, Microbial / genetics
Feasibility Studies
Genes, Viral
Genetic Markers*
Genetic Vectors
Herpesvirus 4, Human / genetics*
Hodgkin Disease / virology*
Humans
Injections, Intravenous
Neomycin / pharmacology*
Neoplasm Recurrence, Local
Retroviridae / genetics
T-Lymphocytes, Cytotoxic*

Substances

Anti-Bacterial Agents
Genetic Markers
Neomycin